Clinical Trials Browser

INDUSTRY × Breast Neoplasms × MK 2206 × Clear all

NCT00963547 2024-06-04

MK-2206-015

Phase 1 Terminated

33 enrolled 13 charts

Breast Neoplasms

NCT01295632 2015-08-27

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Phase 1 Completed

BreastCNSGynecologic

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms